Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Hajime Yurugi"'
Autor:
Kristina Riegel, Hajime Yurugi, Janine Schlöder, Helmut Jonuleit, Manuel Kaulich, Friederike Kirschner, Danielle Arnold-Schild, Stefan Tenzer, Hansjörg Schild, Krishnaraj Rajalingam
Publikováno v:
Cell Death and Disease, Vol 12, Iss 11, Pp 1-14 (2021)
Abstract Tumors exhibit a variety of strategies to dampen antitumor immune responses. With an aim to identify factors that are secreted from tumor cells, we performed an unbiased mass spectrometry-based secretome analysis in lung cancer cells. Interl
Externí odkaz:
https://doaj.org/article/98255791638d4d7f9a6010011fe837a6
Autor:
Nora Chouha, Hussein Abou-Hamdan, Hajime Yurugi, Riku Yoshii, Hiromi Ii, Ahmad Najem, Ghanem E. Ghanem, Susumu Nakata, Krishnaraj Rajalingam, Yu Peng, Dong Wang, Canan G. Nebigil, Laurent Désaubry
Publikováno v:
European Journal of Medicinal Chemistry
European Journal of Medicinal Chemistry, 2022, 242, pp.114635. ⟨10.1016/j.ejmech.2022.114635⟩
European Journal of Medicinal Chemistry, 2022, 242, pp.114635. ⟨10.1016/j.ejmech.2022.114635⟩
Fluorizoline is a cytotoxic trifluorothiazoline that targets the scaffold proteins prohibitins-1 and -2 (PHB1/2) to inhibit the kinase C-RAF and promote the expression of the cyclin-dependent kinase inhibitor p21 to induce cancer cell death. In melan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cc9b51a7fa505ea1d0e6306f4d0fe36
https://hal.science/hal-03806694
https://hal.science/hal-03806694
Autor:
Petros Kechagioglou, Camille Dupont, Hajime Yurugi, Alexey Chernobrovkin, Kristina Riegel, Stephen Cosenza, Steven M. Fruchtman, Krishnaraj Rajalingam
Publikováno v:
Molecular Cancer Research. 21:A020-A020
Background: The importance of styryl benzyl sulfones that induce G2/M cell cycle arrest and apoptosis in tumor cells has raised interest in cancer therapeutics. Rigosertib (ON 01910.Na) has been characterized as a disruptor of multiple signaling path
Autor:
Petros Kechagioglou, Camille Dupont, Hajime Yurugi, Ute Distler, Stefan Tenzer, Alexey Chernobrovkin, Kristina Riegel, Juliane Mooz, Mahil Lambert, Volker Dötsch, Stephen Cosenza, Steven M. Fruchtman, Krishnaraj Rajalingam
Publikováno v:
Cancer Research. 83:5987-5987
CDK4/6 inhibitors are clinically approved for the treatment of HR+, HER2- metastatic breast cancer by reinstating the G1/S checkpoint in tumor cells. Despite clinical benefit, safety concerns such as neutropenia and diarrhea, and disease progression,
Autor:
Judith Stickdorn, Lara Stein, Danielle Arnold-Schild, Jennifer Hahlbrock, Carolina Medina-Montano, Joschka Bartneck, Tanja Ziß, Evelyn Montermann, Cinja Kappel, Dominika Hobernik, Maximilian Haist, Hajime Yurugi, Marco Raabe, Andreas Best, Krishnaraj Rajalingam, Markus P. Radsak, Sunil A. David, Kaloian Koynov, Matthias Bros, Stephan Grabbe, Hansjörg Schild, Lutz Nuhn
Publikováno v:
ACS Nano
The generation of specific humoral and cellular immune responses plays a pivotal role in the development of effective vaccines against tumors. Especially the presence of antigen-specific, cytotoxic T cells influences the outcome of therapeutic cancer
Autor:
Petros Kechagioglou, Camille Dupont, Hajime Yurugi, Ute Distler, Stefan Tenzer, Alexey Chernobrovkin, Kristina Riegel, Stephen Cosenza, Steven M. Fruchtman, Krishnaraj Rajalingam
Publikováno v:
Journal of Clinical Oncology. 40:e15096-e15096
e15096 Background: Despite clinical benefit of CDK4/6 inhibitors in HR+Her2-mBC, patients progress. Neutropenia and diarrhea are safety concerns. Narazaciclib (ON 123300) is a multi-targeted kinase inhibitor of CDK4/6, ARK5 (NUAK1), CSF1R, and c-Kit
Autor:
Amel Djehal, Dong Wang, Laurent Désaubry, Peng Yu, Sabria Elderwish, Redouane Tabti, Hajime Yurugi, Canan G. Nebigil, Krishnaraj Rajalingam, Hussein Abou-Hamdan
Publikováno v:
Cellular and Molecular Life Sciences
Cellular and Molecular Life Sciences, Springer Verlag, 2020, 77 (18), pp.3525-3546. ⟨10.1007/s00018-020-03475-1⟩
Cellular and Molecular Life Sciences, Springer Verlag, 2020, 77 (18), pp.3525-3546. ⟨10.1007/s00018-020-03475-1⟩
Over the last three decades, the scaffold proteins prohibitins-1 and -2 (PHB1/2) have emerged as key signaling proteins regulating a myriad of signaling pathways in health and diseases. Small molecules targeting PHBs display promising effects against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2f9e5ea2ee35308e854c5644c8cc413
https://hal.archives-ouvertes.fr/hal-03014862
https://hal.archives-ouvertes.fr/hal-03014862
Autor:
Wenting Zhao, Krishnaraj Rajalingam, Yong Zhou, Yinyin Zhuang, Sebastian Rosigkeit, Ernesto Bockamp, Farid Ahmad Siddiqui, Laurent Désaubry, Hajime Yurugi, Hong Liang, Hussein Abou-Hamdan, Daniel Abankwa, Yongpeng Zeng
Publikováno v:
Journal of Cell Science
Journal of Cell Science, Company of Biologists, 2020, 133 (12), pp.jcs244111. ⟨10.1242/jcs.244111⟩
Journal of Cell Science, Company of Biologists, 2020, 133 (12), pp.jcs244111. ⟨10.1242/jcs.244111⟩
The RAS oncogenes are frequently mutated in human cancers and among the three isoforms (KRAS, HRAS and NRAS), KRAS is the most frequently mutated oncogene. Here, we demonstrate that a subset of flavaglines, a class of natural anti-tumour drugs and ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ca3ff72c3d13cf07fb8ce032b011015
http://orbilu.uni.lu/handle/10993/45635
http://orbilu.uni.lu/handle/10993/45635
Autor:
Hajime Yurugi, Edgar Schmitt, Daniel Spitzer, Natascha Stergiou, David Straßburger, Dieter Schollmeyer, Pol Besenius, Moritz Urschbach
Publikováno v:
ChemBioChem. 19:912-916
A modular route to prepare functional self-assembling dendritic peptide amphiphiles decorated with mannosides, to effectively target antigen-presenting cells, such as macrophages, is reported. The monomeric building blocks were equipped with tetra(et
Autor:
Dong, Wang, Redouane, Tabti, Sabria, Elderwish, Hussein, Abou-Hamdan, Amel, Djehal, Peng, Yu, Hajime, Yurugi, Krishnaraj, Rajalingam, Canan G, Nebigil, Laurent, Désaubry
Publikováno v:
Cellular and molecular life sciences : CMLSReferences. 77(18)
Over the last three decades, the scaffold proteins prohibitins-1 and -2 (PHB1/2) have emerged as key signaling proteins regulating a myriad of signaling pathways in health and diseases. Small molecules targeting PHBs display promising effects against